700 Main Street
13 articles with Glympse Bio
Glympse Bio (Glympse), a biotechnology company advancing the way diseases are understood, tracked, and treated, has closed an oversubscribed $46.7 million Series B financing. The proceeds from the financing will support continu
Glympse Bio secured $46.7 million in a Series B fundraising round that will be used to support continued development of the company’s novel biosensor platform in fibrotic diseases such as Non-Alcoholic Steatohepatitis (NASH), oncology, and infectious diseases.
Glympse Bio Presents Preclinical Data Supporting Its Technology’s Potential to Improve NASH Patient Management
Data supports high diagnostic accuracy of proprietary synthetic biomarkers for early monitoring of stage of disease, disease progression and treatment response
11/8/2019Pharmaceutical, medtech and biotech companies expand their leadership teams with this week's appointments.
Biotech and pharmaceutical executive brings expertise leading new development programs and operating models
Glympse Bio, Inc., a life science company developing in vivo activity sensors to transform disease detection, monitoring and drug response, announced today that Francis Cuss has been appointed to its Board of Directors
5/17/2019Biopharma companies add new leaders to executive roles and boards of directors.
Skilled Operational and Scientific Leader Brings More than 15 Years of Molecular Genetics Experience
Glympse Bio, Inc., a life science company developing in vivo activity sensors to transform disease monitoring, announced today that it has been named by FierceMedTech as one of 2018’s Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
New Year, fresh start? Could be. WalletHub recently compared more than 180 cities across the U.S., using 30 key indicators to evaluate their job strength. Some of those factors were job opportunities, employment growth, monthly average starting salary and employment outlook.
12/10/2018Biotech and pharma companies strengthen their leadership teams with these appointments. Who made power moves in the industry this past week?
Stanley Lapidus appointed as Chairman of the Board; Dr. Robert Langer appointed to the Board of the Directors; Co-Founder Dr. Sangeeta Bhatia to lead Scientific Advisory Board
Top-Tier Investor Syndicate and Strategic Pharma Partner back a Novel Model for Sensing Diseases